Pipeline

March 12, 2018

Company	Drug/Device	Medical Condition	Status
Seattle Genetics, Inc.	SGN-CD48A	Relapsed or refractory multiple myeloma	Phase I trial initiated enrolling 75 subjects
Daiichi Sankyo Company, Ltd.	DS-8201	HER2-expressing advanced colorectal cancer	Phase II trial initiated enrolling 50 subjects in North America, Europe and Japan
GTx, Inc.	Enobosarm	Stress urinary incontinence (SUI)	Phase II trial initiated enrolling 18 female subjects
InflaRx	IFX-1	Moderate or severe Hidradenitis Suppertiva (HS)	Phase IIb trials initiated enrolling 175 subjects in the U.S., Germany, Greece, Denmark and the Netherlands
Aimmune Therapeutics, Inc.	AR101	Peanut allergy	Phase III trials initiated enrolling 850 subjects ages 4-49
Vanda Pharmaceuticals, Inc.	Hetlioz	Jet lag disorder	Phase III trials initiated enrolling 318 subjects
Biohaven Pharmaceutical Holding Company Ltd.	Zydis ODT formulation of rimegepant	Migraine	Phase III trials initiated enrolling 850 subjects
Bioverativ, Inc	BIVV009	Cold agglutinin disease	Phase III trials initiated
MeiraGTx	AAOO2	Achromatopsia	PRIME designation grated by the EMA
Tocagen Inc.	Toca 511 (vocimagene amiretrorepvec) & Toca FC (flucytosine)	Glioma	Orphan drug designated granted by the EMA
InVivo Therapeutics Holdings Corp.	Neuro-Spinal Scaffold	Acute spinal cord injury (SCI)	FDA approval granted
Polyganics	Liver and Pancreas Sealant Patch	Fluid leakage after hepato-pancreato-biliary (HPB) procedures	FDA breakthrough device designation granted

Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Pipeline